Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 1048 of 5804
-
New depression pill JS1-1-01 enters key trials
Symptom relief Not yet recruitingThe purpose of this study is to evaluate the Effectiveness and Safety of JS1-1-01 Tablet in Patients With Moderate to Severe Depression
Phase: PHASE2, PHASE3 • Sponsor: Tasly Pharmaceutical Group Co., Ltd • Aim: Symptom relief
Last updated Jun 27, 2026 12:05 UTC
-
Could a sleep drug lift depression? new trial seeks answers
Symptom relief Recruiting nowThe main purpose of this study is to assess how well the study drug (JNJ-42847922) works (efficacy) compared with placebo in improving depressive symptoms in participants with major depressive disorder (\[MDD\], a common mood disorder that causes a lasting feeling of sadness and …
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Symptom relief
Last updated Jul 08, 2026 00:00 UTC
-
New drug cocktail aims to beat tough infection in HIV patients
Disease control Not yet recruitingBackground: Disseminated Mycobacterium avium complex (MAC) infection remains a serious opportunistic infection in patients with advanced HIV infection, particularly among those with severe immunosuppression. Despite the widespread use of antiretroviral therapy (ART), disseminate…
Phase: NA • Sponsor: Shanghai Public Health Clinical Center • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Heart rhythm breakthrough? new ablation method targets stubborn AF
Disease control Not yet recruitingThis prospective, multicenter, randomized controlled study was designed to investigate the feasibility, efficacy and safety of pulsed field ablation (PFA) strategies for persistent atrial fibrillation. For patients with persistent atrial fibrillation and normal left atrial substr…
Phase: NA • Sponsor: Hangzhou Dinova EP Technology Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New injection aims to revive immune system in HIV patients
Disease control Not yet recruitingThe Phase Ib clinical trial is an add-on study based on combination antiretroviral therapy (cART). It adopts a multicenter, randomized, double-blind, placebo-controlled, multiple-dose design to evaluate the safety and efficacy of multiple intramuscular injections of JL18008 added…
Phase: PHASE1, PHASE2 • Sponsor: Jecho Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
AI brain zaps aim to unlock paralyzed fingers in stroke survivors
Symptom relief Not yet recruitingThe goal of this clinical study is to evaluate whether AI-based customized transcranial direct current stimulation (tDCS) using MR images is more effective than sham stimulation in improving finger motor function in patients with finger paralysis caused by subacute stroke. The ma…
Phase: NA • Sponsor: NEUROPHET • Aim: Symptom relief
Last updated Jun 27, 2026 12:00 UTC
-
Heart scan could spot Parkinson's early
Diagnosis Recruiting nowThis is a Phase 2 study evaluating the positron-emitting radiopharmaceutical 18F-mFBG as an imaging agent for quantification of the effect of neurodegenerative diseases on myocardial sympathetic innervation. Effectiveness of 18F-mFBG imaging of the heart will be judged in terms o…
Phase: PHASE2 • Sponsor: Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) • Aim: Diagnosis
Last updated Jul 03, 2026 00:00 UTC
-
New drug JY016 targets EGFR-Positive cancers in early trial
Disease control Not yet recruitingThis study is a single-arm, open-label, multi-center Phase I/II clinical trial, consisting of Part A: the Phase I dose escalation stage, and Part B: the Phase II expansion stage. The objective of the Phase I dose escalation stage is to evaluate the safety, pharmacokinetic charact…
Phase: PHASE1, PHASE2 • Sponsor: Biotech Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Experimental drug SHR-A1904 takes on rare cancer
Disease control Not yet recruitingThis is a prospective, single-center, phase II trial designed to evaluate the efficacy and safety of SHR-A1904 monotherapy in second-line or later treatment of advanced neuroendocrine carcinoma. The primary endpoint is the objective response rate. Secondary endpoints include prog…
Phase: PHASE2 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New drug ES014 targets desmoid tumors in Mid-Stage trial
Disease control Recruiting nowThis is an open-label, multicenter, single-arm phase 2 clinical study designed to evaluate the efficacy, safety, tolerability, patient-reported outcomes (PROs), pharmacokinetics (PK), anti-drug antibody (ADA) and pharmacodynamics (PD) of ES014 in adult desmoid tumor patients.
Phase: PHASE2 • Sponsor: Elpiscience (Suzhou) Biopharma, Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Nanobody-Powered CAR-Ts take on tough lymphoma
Disease control Not yet recruitingThis is a single arm study to evaluate the safety and efficacy of Nanobody-Based CD19/CD20 Tandem Dual CAR-T-cell therapy for Relapsed/Refractory B-Cell Lymphoma
Phase: EARLY_PHASE1 • Sponsor: Affiliated Hospital to Academy of Military Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Heart-Safe chemo? new study tests vasodilators to prevent chest pain in cancer patients
Disease control Recruiting nowThis phase I/II trial compares the effect of drugs that causes widening of blood vessels as a result of smooth muscle relaxation (vasodilator therapy) with isosorbide mononitrate, diltiazem or placebo to reduce vasotoxicity in patients with gastrointestinal cancer receiving fluor…
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Could an HIV drug tame brain inflammation in Alzheimer's?
Disease control Recruiting nowThe present study will administer the drug leronlimab to 20 participants who are above 50 years old with Alzheimer's disease (AD) or mild cognitive impairment (MCI) due to AD. While leronlimab is considered safe in other diseases like Human Immunodeficiency Virus (HIV) and certai…
Phase: PHASE2 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New portable device could bring glaucoma screening to remote areas
Diagnosis Recruiting nowThe current situation outside of large cities in lower-income countries, as described above, is suboptimal for the diagnosis of glaucoma. Doctors have no means of assessing visual fields, and as such may not be able to identify the condition until too advanced for any meaningful …
Phase: NA • Sponsor: Buckinghamshire Healthcare NHS Trust • Aim: Diagnosis
Last updated Jul 01, 2026 00:00 UTC
-
Selenium supplements may boost ulcerative colitis treatment
Disease control Recruiting nowMicronutrient deficiencies are common in ulcerative colitis (UC). Selenium deficiency is associated with worse disease outcomes including disease flares and need for surgery. Previous in vitro and in vivo studies demonstrated that selenium regulates colonic inflammation, and that…
Phase: PHASE2 • Sponsor: Northwestern University • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Brain cancer radiotherapy gets a precision boost from advanced MRI
Disease control Recruiting nowThis is a research study to determine if a novel molecular magnetic resonance imaging (MRI) technique, called amide proton transfer (APT) imaging, is useful in identifying the most aggressive areas of tumor needed for radiotherapy of brain tumors.
Phase: NA • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New shot for stubborn constipation pain enters Mid-Stage trial
Symptom relief Recruiting nowThe purpose of this study is to evaluate how well brenipatide (LY3537031) is tolerated what side effects may occur, and the safety and efficacy in participants with Irritable Bowel Syndrome-Constipation (IBS-C). The study drug will be administered subcutaneously (SC) (under the s…
Phase: PHASE2 • Sponsor: Eli Lilly and Company • Aim: Symptom relief
Last updated Jul 19, 2026 00:00 UTC
-
New catheter targets pancreatic cancer tumors directly
Disease control Recruiting nowThis study is testing a new way to deliver the chemotherapy drug Gemcitabine in pancreatic tumors using the catheter Extroducer® Infusion Catheter System. The study will include patients with Locally Advanced Pancreatic Cancer that cannot be removed with surgery. Patients will r…
Phase: PHASE1, PHASE2 • Sponsor: Smartwise Sweden AB • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Can yoga and values training ease the stress of parenting a child with special needs?
Symptom relief Recruiting nowParents of children with special needs often experience high levels of stress and difficulties in emotional regulation, which may negatively affect both their well-being and parent-child interactions. This study aims to evaluate the effect of a Comfort Theory-based yoga and value…
Phase: NA • Sponsor: Ankara Yildirim Beyazıt University • Aim: Symptom relief
Last updated Jun 27, 2026 13:03 UTC
-
New drug trial targets rare, aggressive cancer subtype
Disease control Recruiting nowPhase II open label study designed to evaluate the efficacy and safety of P-Sam in patients with aggressive, solid, NOTCH mutant or p63 low (B7-H4 high) R/M ACC-I patients.
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC